Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study - Petrakis, Ioannis; Kontogiorgis, Christos; Nena, Evangelia; Delimpasi, Sosana; Loutsidi, Natasa E.; Spanoudakis, Emmanouil; Intzes, Stergios; Misidou, Christina; Symeonidou, Marianthi; Giannakoulas, Nikolaos; Constantinidis, Theodoros C.; Terpos, Evangelos (Cancers, 2023)
Keywords: Analysis; Antimitotic agents; Antineoplastic agents; Bortezomib; Care and treatment; Clinical outcomes; Clinical trials; Drug approval; Enrollments; Health care policy; Immunotherapy; Innovations; Malignancy; Medical innovations; Medical research; Medicine, Experimental; Missing data; Multiple myeloma; Oncology; Patient outcomes; Patients; Pharmaceuticals; Pharmacoeconomics; Remission; Statistical analysis; Targeted cancer therapy; Greece; Eastern Europe; multiple myeloma; real world; daratumumab; pomalidomide; carfilzomib; ixazomib